These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15233225)

  • 41. Incidental control of rosacea by somatostatin.
    Piérard-Franchimont C; Quatresooz P; Piérard GE
    Dermatology; 2003; 206(3):249-51. PubMed ID: 12673083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study.
    McCombe M; Lightman S; Eckland DJ; Hamilton AM; Lightman SL
    Eye (Lond); 1991; 5 ( Pt 5)():569-75. PubMed ID: 1686591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Somatostatin: physiologic significance and therapeutic applications].
    Gómez-Pan A
    Rev Clin Esp; 1987 May; 180(8):413-5. PubMed ID: 2887011
    [No Abstract]   [Full Text] [Related]  

  • 44. GH/IGF-I axis in severe systemic disorders.
    De Feo P
    J Endocrinol Invest; 2002 Jun; 25(6):491-2. PubMed ID: 12109617
    [No Abstract]   [Full Text] [Related]  

  • 45. Growth hormone/insulin-like growth factor-I axis in aging: a summary of a National Institutes of Aging-Sponsored Symposium.
    Rosen CJ; Conover C
    J Clin Endocrinol Metab; 1997 Dec; 82(12):3919-22. PubMed ID: 9398687
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Response to Grant et al.
    Gehrs KM
    Diabetes Care; 2001 Jan; 24(1):182-3. PubMed ID: 11194232
    [No Abstract]   [Full Text] [Related]  

  • 47. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
    Pollak M; Gallant K; Poisson R; Harris A
    Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatostatin and octreotide: physiological background and pharmacological application.
    Beglinger C; Drewe J
    Digestion; 1999; 60 Suppl 2():2-8. PubMed ID: 10207225
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical aspects and pathophysiology of diabetic retinopathy. Conclusions for the private practice].
    Schumacher H
    Med Welt; 1966 Jan; 2():96-100. PubMed ID: 5960633
    [No Abstract]   [Full Text] [Related]  

  • 50. [The role of somatostatin in diabetic disease].
    Leonardi R; Toffoli C; Rigamonti D; Rigamonti L
    Arch Sci Med (Torino); 1981; 138(1):11-5. PubMed ID: 6113823
    [No Abstract]   [Full Text] [Related]  

  • 51. Proliferative retinopathy with growth hormone deficiency and diabetes mellitus.
    Quin JD; MacCuish AC; Gordon D
    BMJ; 1990 Jun; 300(6739):1586-7. PubMed ID: 2372634
    [No Abstract]   [Full Text] [Related]  

  • 52. Somatostatin and analogues in portal hypertension.
    Abraldes JG; Bosch J
    Hepatology; 2002 Jun; 35(6):1305-12. PubMed ID: 12029614
    [No Abstract]   [Full Text] [Related]  

  • 53. [Somatostatin].
    German SV
    Klin Med (Mosk); 1987 Oct; 65(10):9-15. PubMed ID: 2892967
    [No Abstract]   [Full Text] [Related]  

  • 54. [Does a medical treatment of diabetic retinitis exist?].
    Vérin ; Peyresblanques J; Yacoubi
    Bull Soc Ophtalmol Fr; 1971 Jan; 71(1):127-32. PubMed ID: 5113081
    [No Abstract]   [Full Text] [Related]  

  • 55. Insulin. A memory hormone?
    Harv Health Lett; 2000 Feb; 25(4):7. PubMed ID: 10637018
    [No Abstract]   [Full Text] [Related]  

  • 56. Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus.
    Iwona BS
    Curr Neuropharmacol; 2016; 14(8):792-804. PubMed ID: 27528260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

  • 58. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The growth hormone hypothesis - 2005 revision.
    Frystyk J
    Horm Metab Res; 2005 Apr; 37 Suppl 1():44-8. PubMed ID: 15918110
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors.
    Davis MI; Wilson SH; Grant MB
    Horm Metab Res; 2001 May; 33(5):295-9. PubMed ID: 11440276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.